Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

59256.1 IP-LS

Titre du projet

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Titre du projet anglais

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte		-	-
Résumé des résultats (Abstract)		-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Allemand)	Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease
Description succincte (Anglais)	Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease
Résumé des résultats (Abstract) (Allemand)	In this project PharmaBiome#s Functional Consortium (PB-FC) designed for the treatment of gut dysbiosis in acute graft-versus-host disease (aGvHD) patients will be tested in mouse models to answer essential questions for the successful translation of our novel, function-based approach.